Clinical use of bone-targeting radiopharmaceuticals with focus on alpha-emitters - Abstract

Various single or multi-modality therapeutic options are available to treat pain of bone metastasis in patients with prostate cancer.

Different radionuclides that emit β-rays such as 153Samarium and 89Strontium and achieve palliation are commercially available. In contrast to β-emitters, 223Radium as a α-emitter has a short path-length. The advantage of the α-emitter is thus a highly localized biological effect that is caused by radiation induced DNA double-strand breaks and subsequent cell killing and/or limited effectiveness of cellular repair mechanisms. Due to the limited range of the α-particles the bone surface to red bone marrow dose ratio is also lower for 223Radium which is expressed in a lower myelotoxicity. The α emitter 223Radium dichloride is the first radiopharmaceutical that significantly prolongs life in castrate resistant prostate cancer patients with wide-spread bone metastatic disease. In a phase III, randomized, double-blind, placebo-controlled study 921 patients with castration-resistant prostate cancer and bone metastases were randomly assigned. The analysis confirmed the 223Radium survival benefit compared to the placebo (median, 14.9 mo vs 11.3 mo; P < 0.001). In addition, the treatment results in pain palliation and thus, improved quality of life and a delay of skeletal related events. At the same time the toxicity profile of 223Radium was favourable. Since May 2013, 223Radium dichloride (Xofigo®) is approved by the US Food and Drug Administration.

Written by:
Wieder HA, Lassmann M, Allen-Auerbach MS, Czernin J, Herrmann K.   Are you the author?
Hinrich A Wieder, Department of Radiology, Zentrum für Radiologie und Nuklearmedizin, 41515 Grevenbroich, Germany.

Reference: World J Radiol. 2014 Jul 28;6(7):480-5.
doi: 10.4329/wjr.v6.i7.480


PubMed Abstract
PMID: 25071888

 

 

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe